Ximelagatran for the secondary prevention of venous thromboembolism
- 1 January 2005
- journal article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 94 (10) , 820-824
- https://doi.org/10.1160/th05-04-0228
Abstract
Schattauer GmbH - Verlag für Medizin und Naturwissenschaften ist ein renommierter Herausgeber von Fachbüchern, -zeitschriften und -software. Besuchen Sie unser Internetangebot mit Onlinezugang zu unseren ZeitschriftenartikelnKeywords
Funding Information
- AstraZeneca Research and Development
This publication has 23 references indexed in Scilit:
- The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS studyJournal of Thrombosis and Haemostasis, 2003
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor XimelagatranNew England Journal of Medicine, 2003
- Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee ReplacementNew England Journal of Medicine, 2003
- No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor XimelagatranClinical Pharmacokinetics, 2003
- No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male VolunteersClinical Pharmacokinetics, 2003
- Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug InteractionsClinical Pharmacokinetics, 2003
- Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin InhibitorClinical Pharmacokinetics, 2003
- A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE IJournal of Thrombosis and Haemostasis, 2003
- A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous ThromboembolismNew England Journal of Medicine, 1999